INOVIO to Showcase HPV and COVID-19 DNA Medicine Data at Key Conferences
Event summary
- INOVIO will present data on DNA immunotherapy INO-3107 at the Eurogin HPV Conference on March 19, 2026.
- The presentation will highlight long-term surgical intervention reduction in HPV-6 & 11 RRP.
- INOVIO will also present at the World Vaccine Congress DC on March 30, 2026, focusing on DNA-encoded monoclonal antibody technology for COVID-19.
- Abstracts from both presentations will be shared on INOVIO's website post-conference.
The big picture
INOVIO's participation in these conferences underscores its focus on advancing DNA medicine for HPV and infectious diseases. The presentations come at a time when the biotech sector is increasingly exploring innovative approaches to vaccine development and immunotherapy. The success of INOVIO's technologies could position it as a key player in the evolving landscape of DNA-based treatments.
What we're watching
- Clinical Validation
- How the data from INO-3107 presentation will impact its clinical validation and regulatory pathway.
- Market Differentiation
- Whether INOVIO's DNA-encoded monoclonal antibody technology can differentiate it in the competitive COVID-19 vaccine market.
- Investor Sentiment
- The pace at which investor sentiment shifts based on the conference presentations and subsequent data releases.
Related topics